42 results about "Cardiac myocyte proliferation" patented technology

The present invention discloses a set of human microRNAs, or a primary transcript for such microRNAs, or a precursor of such microRNAs, or a mimic of such microRNAs or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening microRNAs and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes.

The invention relates to compostions and methods for promoting cellular proliferation and de-differentiation of cells into stem cells to foster tissue regeneration. Specifically, the invention relates to transiently administering a microRNA (miR) or its mimic for promoting cardiomyocyte proliferation and cardiac regeneration.

The present invention discloses a set of human microRNAs, or a primary transcript for such microRNAs, or a precursor of such microRNAs, or a mimic of such microRNAs or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening microRNAs and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes.

Provided is the use of a novel heterocyclic derivative having cardiomyocyte proliferative activity for the treatment of heart diseases. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, solvates, stereoisomers or prodrugs thereof; and their use. The definition of each group in the formula can be detailed in the specification.

An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding lysine-specific demethylase 4D (KDM4D); (b) a promoter that induces or effects overexpression of KDM4D, wherein the promoter is operably linked to the nucleic acid sequence; and (c) a regulatory element that inducibly represses the overexpression of KDM4D. The vector can be administered to a subject in a method for inducing tissue-specific hyperplasia in a mammal, including cardiomyocyte proliferation. The method provides for regenerative therapy, including improving cardiac function after myocardial infarct and other forms of cardiac damage.

The invention relates to a deer heart protein hydrolyzate, a preparation method and application thereof, and belongs to the technical field of biomedicine. The preparation method comprises the following steps: pretreatment: taking deer heart, adding physiological saline, and homogenizing tissue to obtain an enzymolysis stock solution for use; enzymolysis: taking the above enzymolysis stock solution, adding pepsin for enzymolysis reaction, and obtaining Enzymatic hydrolysis solution; purification: take the above enzymatic hydrolysis solution, separate and purify it with a Sephadex column, and take a 3KD-15KD polypeptide to obtain it. In the present invention, the heart of sika deer is used as raw material, and the small molecular polypeptide substance is obtained through tissue homogenization and a suitable enzymatic hydrolysis method. And the aging cardiomyocyte model was established, and the effect of various enzymatic hydrolyzates on the proliferation rate of cardiomyocytes was detected by MTT method. The experiment confirmed that the obtained deer heart protein hydrolyzate has good activity in alleviating the aging of cardiomyocytes.

The invention discloses a medicine application of phenylephrine. The use is the application of phenylephrine or its pharmaceutically acceptable salts and esters in the preparation of drugs for promoting cardiomyocyte proliferation. The present invention proves through experiments that phenylephrine can promote the proliferation of rat cardiomyocytes. Therefore, phenylephrine can be used in related fields such as preparation of drugs for promoting myocardial cell proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.

The invention discloses the use of agricaridone in antagonizing myocardial cell injury caused by hypoxia. According to the research of the present invention, Agrimony lactone can protect cardiomyocyte damage caused by hypoxia by promoting the proliferation of cardiomyocytes, inhibiting apoptosis caused by hypoxia, maintaining the integrity of cell morphology and enhancing the function of mitochondria , providing theoretical support for the development of new drugs for the treatment of myocardial infarction.

The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.

The invention discloses a new medicine application of AZD3965. The new use is the application of AZD3965 or its pharmaceutically acceptable salts and esters in the preparation of drugs for promoting cardiomyocyte proliferation. The present invention proves through experiments that AZD3965 can promote the proliferation of cardiomyocytes in rats and the cytokinesis of cardiomyocytes in newborn mice with MADM. Therefore, AZD3965 can be used in related fields such as preparation of drugs for promoting myocardial cell proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.